ASC-话题@MedSci

#ASC#

1352篇内容 | 3995人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1939120, encodeId=676d19391201d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Catheter Cardiovasc Interv：R-ZES在ST-Elevation心肌梗死患者中的安全性和有效性——Resolute-STEMI试验, objectType=article, longId=203341, objectId=5b9320334148, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b9320334148, replyNumber=0, likeNumber=78, createdTime=2021-01-12, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b9320334148, moduleTitle=Catheter Cardiovasc Interv：R-ZES在ST-Elevation心肌梗死患者中的安全性和有效性——Resolute-STEMI试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b9320334148)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939201, encodeId=386c1939201ca, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO-2021速递：复发胶质母细胞瘤，Nivolumab联合标准贝伐单抗可使年龄较大的患者受益, objectType=article, longId=212406, objectId=efa62124062e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efa62124062e, replyNumber=0, likeNumber=91, createdTime=2021-10-17, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efa62124062e, moduleTitle=ASCO-2021速递：复发胶质母细胞瘤，Nivolumab联合标准贝伐单抗可使年龄较大的患者受益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efa62124062e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939114, encodeId=6c0d193911460, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Circ Cardiovasc Interv：使用自膨胀镍钛诺支架专用静脉支架可有效且安全的治疗有症状的髂股静脉阻塞——VIRTUS试验结果, objectType=article, longId=203296, objectId=027320329659, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=027320329659, replyNumber=0, likeNumber=66, createdTime=2020-12-31, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=027320329659, moduleTitle=Circ Cardiovasc Interv：使用自膨胀镍钛诺支架专用静脉支架可有效且安全的治疗有症状的髂股静脉阻塞——VIRTUS试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=027320329659)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939123, encodeId=d4cc193912330, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO-GI 2020：Bemarituzumab的II期FIGHT试验取得积极结果, objectType=article, longId=204372, objectId=c6472043e202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6472043e202, replyNumber=0, likeNumber=68, createdTime=2021-11-24, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6472043e202, moduleTitle=ASCO-GI 2020：Bemarituzumab的II期FIGHT试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6472043e202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939139, encodeId=f60519391393d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GU 2021: 转移性肾细胞癌一线采用免疫治疗效果如何？, objectType=article, longId=207195, objectId=8fad20e19548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fad20e19548, replyNumber=0, likeNumber=79, createdTime=2021-07-19, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fad20e19548, moduleTitle=ASCO GU 2021: 转移性肾细胞癌一线采用免疫治疗效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fad20e19548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939160, encodeId=729c193916099, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle= J Stroke Cerebrovasc Dis：机器人康复训练联合VR技术可显著改善慢性卒中患者的认知和行为, objectType=article, longId=211385, objectId=822d21138591, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=822d21138591, replyNumber=0, likeNumber=110, createdTime=2022-03-19, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=822d21138591, moduleTitle= J Stroke Cerebrovasc Dis：机器人康复训练联合VR技术可显著改善慢性卒中患者的认知和行为, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=822d21138591)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939168, encodeId=fd601939168ad, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021: 摘要概览与展望 5 | 丹娜—法伯癌症研究所ASCO关键研究关注, objectType=article, longId=211839, objectId=d07121183975, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d07121183975, replyNumber=0, likeNumber=84, createdTime=2021-07-18, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d07121183975, moduleTitle=ASCO 2021: 摘要概览与展望 5 | 丹娜—法伯癌症研究所ASCO关键研究关注, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d07121183975)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939317, encodeId=09e4193931e86, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ESC 2021丨FOURIER全新结果：依洛尤单抗显著降低ASCVD患者所有血管床急性动脉事件的风险, objectType=article, longId=216528, objectId=e73f216528e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e73f216528e7, replyNumber=0, likeNumber=63, createdTime=2021-09-15, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e73f216528e7, moduleTitle=ESC 2021丨FOURIER全新结果：依洛尤单抗显著降低ASCVD患者所有血管床急性动脉事件的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e73f216528e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939191, encodeId=1076193919147, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021：荣昌生物ADC新药维迪西妥单抗再次亮相大会，展示重磅临床数据！, objectType=article, longId=212341, objectId=7b272123415c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b272123415c, replyNumber=0, likeNumber=0, createdTime=2022-03-18, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b272123415c, moduleTitle=ASCO 2021：荣昌生物ADC新药维迪西妥单抗再次亮相大会，展示重磅临床数据！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b272123415c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939159, encodeId=89851939159e8, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Journal of Vascular Surgery：TEVAR术中是否施行辅助分支干预手段，与不良预后无关, objectType=article, longId=211322, objectId=a6962113228d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6962113228d, replyNumber=0, likeNumber=56, createdTime=2021-12-12, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6962113228d, moduleTitle=Journal of Vascular Surgery：TEVAR术中是否施行辅助分支干预手段，与不良预后无关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6962113228d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939188, encodeId=8178193918846, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=2021 ASCO大会日程预告1（6月4日）, objectType=article, longId=212252, objectId=99f62122523b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99f62122523b, replyNumber=0, likeNumber=0, createdTime=2021-10-02, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99f62122523b, moduleTitle=2021 ASCO大会日程预告1（6月4日）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99f62122523b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939228, encodeId=36da193922830, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：多因素干预对高危糖尿病肾病患者的MACE风险和死亡率的积极效益, objectType=article, longId=214526, objectId=60f3214526b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60f3214526b7, replyNumber=0, likeNumber=85, createdTime=2021-08-16, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60f3214526b7, moduleTitle=Cardiovasc Diabetol：多因素干预对高危糖尿病肾病患者的MACE风险和死亡率的积极效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60f3214526b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939177, encodeId=6bfd19391e77c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=OCC 2021：Vascepa®中国临床三期研究结果公布：IPE在中国患者中的有效性和安全性得到进一步证实, objectType=article, longId=211942, objectId=78d22119421d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78d22119421d, replyNumber=0, likeNumber=73, createdTime=2022-01-15, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78d22119421d, moduleTitle=OCC 2021：Vascepa®中国临床三期研究结果公布：IPE在中国患者中的有效性和安全性得到进一步证实, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78d22119421d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939212, encodeId=f3da1939212ca, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=2021 ASCO：肝细胞癌领域中国之声, objectType=article, longId=212473, objectId=c86c2124e36d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c86c2124e36d, replyNumber=0, likeNumber=88, createdTime=2022-02-11, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c86c2124e36d, moduleTitle=2021 ASCO：肝细胞癌领域中国之声, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c86c2124e36d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939204, encodeId=3ddf193920455, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021：中国之声！特瑞普利单抗一线治疗复发/转移性鼻咽癌研究取得突破性进展，有望改写国际新标准！, objectType=article, longId=212418, objectId=8c9f212418e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c9f212418e1, replyNumber=0, likeNumber=108, createdTime=2022-04-13, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c9f212418e1, moduleTitle=ASCO 2021：中国之声！特瑞普利单抗一线治疗复发/转移性鼻咽癌研究取得突破性进展，有望改写国际新标准！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c9f212418e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939109, encodeId=a55a1939109ca, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Vasc Health Risk Manag：牙周炎可能是卒中的一个危险因素，尤其是缺血性卒中, objectType=article, longId=201307, objectId=a5b220130e47, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5b220130e47, replyNumber=0, likeNumber=83, createdTime=2021-03-17, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5b220130e47, moduleTitle=Vasc Health Risk Manag：牙周炎可能是卒中的一个危险因素，尤其是缺血性卒中, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5b220130e47)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939164, encodeId=95001939164bb, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021: 摘要概览与展望 2, objectType=article, longId=211710, objectId=08e5211e109c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08e5211e109c, replyNumber=0, likeNumber=74, createdTime=2021-06-11, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08e5211e109c, moduleTitle=ASCO 2021: 摘要概览与展望 2, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08e5211e109c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939224, encodeId=bded19392241e, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Front Cardiovasc Med：肌成纤维细胞来源的外泌体引起心脏内皮细胞功能障碍, objectType=article, longId=213261, objectId=e4902132614e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4902132614e, replyNumber=0, likeNumber=82, createdTime=2021-07-29, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4902132614e, moduleTitle=Front Cardiovasc Med：肌成纤维细胞来源的外泌体引起心脏内皮细胞功能障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4902132614e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939115, encodeId=4daf193911501, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Ann Vasc Surg：Supera支架可有效恢复腘动脉硬化病变患者的血管通畅——真实世界研究结果, objectType=article, longId=203298, objectId=210b2032981a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=210b2032981a, replyNumber=0, likeNumber=59, createdTime=2020-12-18, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=210b2032981a, moduleTitle=Ann Vasc Surg：Supera支架可有效恢复腘动脉硬化病变患者的血管通畅——真实世界研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=210b2032981a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939214, encodeId=6d6c1939214c0, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO2021:德瓦鲁单抗可改善不可切除III期NSCLC患者的5年生存期和无进展生存, objectType=article, longId=212488, objectId=df61212488ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df61212488ed, replyNumber=0, likeNumber=76, createdTime=2022-04-08, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df61212488ed, moduleTitle=ASCO2021:德瓦鲁单抗可改善不可切除III期NSCLC患者的5年生存期和无进展生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df61212488ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASC

2020-05-29

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Catheter Cardiovasc Interv：R-ZES在ST-Elevation心肌梗死患者中的安全性和有效性——Resolute-STEMI试验

2021-01-12

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO-2021速递：复发胶质母细胞瘤，Nivolumab联合标准贝伐单抗可使年龄较大的患者受益

2021-10-17

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Circ Cardiovasc Interv：使用自膨胀镍钛诺支架专用静脉支架可有效且安全的治疗有症状的髂股静脉阻塞——VIRTUS试验结果

2020-12-31

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO-GI 2020：Bemarituzumab的II期FIGHT试验取得积极结果

2021-11-24

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO GU 2021: 转移性肾细胞癌一线采用免疫治疗效果如何？

2021-07-19

quxin068 (审核中...)

前往app查看评论内容

#ASC#

J Stroke Cerebrovasc Dis：机器人康复训练联合VR技术可显著改善慢性卒中患者的认知和行为

2022-03-19

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021: 摘要概览与展望 5 | 丹娜—法伯癌症研究所ASCO关键研究关注

2021-07-18

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ESC 2021丨FOURIER全新结果：依洛尤单抗显著降低ASCVD患者所有血管床急性动脉事件的风险

2021-09-15

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021：荣昌生物ADC新药维迪西妥单抗再次亮相大会，展示重磅临床数据！

2022-03-18

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Journal of Vascular Surgery：TEVAR术中是否施行辅助分支干预手段，与不良预后无关

2021-12-12

quxin068 (审核中...)

前往app查看评论内容

#ASC#

2021 ASCO大会日程预告1（6月4日）

2021-10-02

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：多因素干预对高危糖尿病肾病患者的MACE风险和死亡率的积极效益

2021-08-16

quxin068 (审核中...)

前往app查看评论内容

#ASC#

OCC 2021：Vascepa®中国临床三期研究结果公布：IPE在中国患者中的有效性和安全性得到进一步证实

2022-01-15

quxin068 (审核中...)

前往app查看评论内容

#ASC#

2021 ASCO：肝细胞癌领域中国之声

2022-02-11

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021：中国之声！特瑞普利单抗一线治疗复发/转移性鼻咽癌研究取得突破性进展，有望改写国际新标准！

2022-04-13

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Vasc Health Risk Manag：牙周炎可能是卒中的一个危险因素，尤其是缺血性卒中

2021-03-17

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021: 摘要概览与展望 2

2021-06-11

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Front Cardiovasc Med：肌成纤维细胞来源的外泌体引起心脏内皮细胞功能障碍

2021-07-29

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Ann Vasc Surg：Supera支架可有效恢复腘动脉硬化病变患者的血管通畅——真实世界研究结果

2020-12-18

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO2021:德瓦鲁单抗可改善不可切除III期NSCLC患者的5年生存期和无进展生存

2022-04-08

科室
- - 订阅+
  - 更多科室
工具
服务